The modified program NHL-BFM-90 in the treatment of patients with diffuse large B-cell lymphosarcoma
Magomedova, A.U.; Kravchenko, S.K.; Kremenetskaia, A.M.; Zvonkov, E.E.; Bariakh, E.A.; Margolin, O.V.; Kaplanskaia, I.B.; Vorob'ev, I.A.; Samoĭlova, R.S.; Obukhova, T.N.; Moiseeva, T.N.; Zybunova, E.E.; Gemdzhian, E.G.; Vorob'ev, A.I.
Terapevticheskii Arkhiv 78(10): 44-47
2006
ISSN/ISBN: 0040-3660 PMID: 17180937 Document Number: 597991
Aim. To investigate efficacy of the modified protocol NHL-BFM-90 in patients with diffuse large B-cell lymphosarcoma (DLBCLS).Material and methods. A total of 13 DLBCLS patients with stage II-IV of the disease with affection of lymph nodes at the disease onset (nodal lesion) and stage II with tumor size more than 10 cm (bulky disease) received first-line treatment according to the modified program NHL-BFM-90 from 2002 to 2005. The diagnosis was made by WHO criteria.Results. A complete remission was achieved in 76.9% patients. Resistance to therapy was observed in the patients with bone marrow affection. The 2.5-year overall survival was 74%, 2-year event-free survival was 75% (the events were recurrence and resistance). Follow-up continued from 5 to 47 months.Conclusion. The efficacy of the modified protocol NHL-BFM-90 in DLBCLS patients with stage III-IV of the "nodal" disease and stage 11 of the "bulky" disease was high.